Consequently, development of VRK1 inhibitors can be useful to treat tumor cells by impairing DNA repair processes, which would contribute to improve the efficacy of current treatments independently of the mutational status of p53 and ATM, and by facilitating accumulation of DNA damage that either lead to cell death, or make tumor cells more immunogenic. This evidence concerns the gene VRK1 and neoplasm.